No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 11.6x · 10Y median 14.4x · 23rd percentile · as of Oct 6, 2026
Annual revenue · last 3 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:01:29.137Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T17:01:29.137Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T17:01:29.137Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T17:01:29.137Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T17:01:29.137Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T17:01:29.137Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:01:29.137Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:01:29.137Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for BillionToOne, Inc. (BLLN) stock was $100.42 as of Oct 6, 2026, 1:00 PM EDT, down 7.92% from the previous close.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions.
Medical - Diagnostics & Research · Menlo Park, CA
Next Earnings Date
Oct 6, 2026
Just reported
EPS Estimate
0.16
Revenue Est.
$115.85M
Last Quarter Results
EPS
$0.15
vs Estimate
$0.18
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BLLN | $4.62B | $100.42 | -7.92% | N/A | N/A | N/A | N/A |
| 2OPCH | $4.66B | $31.09 | +33.06% | -14.95% | -1.37% | +5.78% | vs BLLN |
| 3DFTX | $4.66B | $35.12 | -3.06% | +187.00% | +1.43% | N/A | vs BLLN |
| 4LFST | $4.67B | $12.04 | -1.43% | +120.94% | -1.46% | N/A | vs BLLN |
| 5DNTH | $4.71B | $84.18 | -4.39% | +150.87% | -5.50% | N/A | vs BLLN |
| 6HTFL | $4.43B | $51.40 | -1.55% | +38.49% | N/A | N/A | vs BLLN |
8.60
$109.40M
vs Estimate
$109.22M
Consensus Rating
Based on 7 analysts
Average Price Target
$129.00
+28.5% upside
Low
$110.00
Current
$100.42
High
$145.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.13 | $0.16 | $0.20 | 3 |
| Quarter ending Dec 2026 | $0.11 | $0.15 | $0.21 | 3 |
| Quarter ending Mar 2027 | $0.20 | $0.21 | $0.22 | 1 |
| Quarter ending Jun 2027 | $0.22 | $0.23 | $0.24 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.73 | $0.79 | $0.91 | 4 |
| FY 2027 | $0.76 | $1.02 | $1.37 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $111.97M | $115.85M | $117.85M | 6 |
| Quarter ending Dec 2026 | $116.85M | $121.11M | $125.80M | 6 |
| Quarter ending Mar 2027 | $125.57M | $130.13M | $135.27M | 3 |
| Quarter ending Jun 2027 | $133.91M | $138.77M | $144.25M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $446.64M | $454.84M | $460.05M | 6 |
| FY 2027 | $553.27M | $573.67M | $584.81M | 6 |
